Jeffrey A Meckler
CIK 1506916 · Co-Chief Executive Officer · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.95M
Companies
5
Total Filings
57
Lifetime Open-Market Net
$122.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 91,500 | $65.71 | $6.01M | -$922.3K | 8 | 2026-05-21 |
| INDP | Co-Chief Executive Officer | 229,929 | $1.29 | $296.6K | $273.6K | 17 | 2026-02-13 |
| Intec Pharma Ltd. (NTEC) Delisted | Chief Executive Officer | 196,761 | $9.63 | $1.89M | $59.3K | 4 | 2020-07-17 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 64,000 | — | — | $350.1K | 10 | 2020-05-19 |
| QLTI | Director | 94,500 | $27.96 | $2.64M | $362.0K | 10 | 2016-06-21 |
Recent Filings · Page 4 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-08-27 | Intec Pharma Ltd. (NTEC) Delisted | Buy (P) | +100,000 | $45.7K | EDGAR |
| 2019-05-10 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2019-04-05 | Intec Pharma Ltd. (NTEC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-11 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,500 | $0 | EDGAR |
| 2017-05-18 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,500 | $0 | EDGAR |
| 2016-06-21 | QLTI | Grant (A) | — | $0 | EDGAR |
| 2016-05-19 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2016-03-17 | — | Buy (P) | +294,118 | $150.0K | |
| 2016-03-07 | Travere Therapeutics, Inc. (RTRX) Delisted | Buy (P) | +5,000 | $76.6K | EDGAR |
| 2016-03-03 | Travere Therapeutics, Inc. (RTRX) Delisted | Buy (P) | +10,000 | $144.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.